Proportion of Patients in the United States Who Fill Their Nirmatrelvir/Ritonavir Prescriptions
Abstract Introduction Although real-world studies demonstrate that those prescribed nirmatrelvir/ritonavir (and particularly within 5 days of symptom onset) are less likely to experience severe COVID-19 outcomes, prior studies show that only a small fraction of patients with COVID-19 who are eligibl...
Kaydedildi:
| Asıl Yazarlar: | , , , , , |
|---|---|
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
Adis, Springer Healthcare
2024-08-01
|
| Seri Bilgileri: | Infectious Diseases and Therapy |
| Konular: | |
| Online Erişim: | https://doi.org/10.1007/s40121-024-01023-z |
| Etiketler: |
Etiket eklenmemiş, İlk siz ekleyin!
|